Related Experiment Video
Updated: Apr 18, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European
Cristina Pamfil1, Antonis Fanouriakis1, Laura Damian1
1Department of Rheumatology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Greece, Department of Rheumatology, Emergency Clinical County Hospital, Cluj-Napoca, Romania, 2nd Department of Neurology, Attikon University Hospital, Medical School, University of Athens, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Biomedical Research Foundation of the Academy of Athens and 4th Department of Internal Medicine, Attikon University Hospital, Medical School, University of Athens, Greece.
Objective:
To compare the European League Against Rheumatism (EULAR) recommendations for the management of NPSLE with usual care in two tertiary centres and to detect potential pitfalls in their use for diagnosis and treatment.
Methods:
A chart-based review of NPSLE manifestations was conducted in two European centres. Diagnostic and treatment decisions were compared against the EULAR recommendations for general NPSLE and specific manifestations.
Results:
We studied a total of 94 patients who experienced 123 lupus-related neuropsychiatric events over 10 years. In 80% of the events, at least one EULAR-defined risk factor (previous NPSLE, generalized disease activity or aPL positivity) was present. Overall, there was good concordance between clinical care and recommendations for diagnosis and treatment (68.7% and 62.7% of events, respectively). Brain MRI was performed in the absence of a clear EULAR recommendation in 42.9% of events; therein, it was more frequently normal compared with imaging performed according to the recommendations (52.4% vs 18.5%, P = 0.008), and it did not influence management. Among patients reporting cognitive dysfunction, only 27.8% underwent the recommended neuropsychological assessment. In line with the recommendations, immunosuppressants were more frequently given in events suggestive of an inflammatory process (80.5% vs 47.6% in non-inflammatory events, P < 0.001). Notably, 52% of cerebrovascular events were managed with combined immunosuppressive/antithrombotic therapy due to either coexisting generalized lupus activity or recurrence despite prior antithrombotic treatment.
Conclusion:
Despite good concordance between EULAR recommendations for NPSLE and usual clinical practice, we identified a number of issues (such as overutilization of brain MRI, suboptimal evaluation of cognitive dysfunction, and frequent use of immunosuppressives in cerebrovascular disease) that need to be investigated further.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome III : Nursing Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...